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To determine the prevalence of vaccine-associated 
paralytic poliomyelitis (VAPP) in immunodeﬁ  cient  infants, 
we reviewed all documented cases caused by immunodeﬁ  -
ciency-associated vaccine-derived polioviruses in Iran from 
1995 through 2008. Changing to an inactivated polio vac-
cine vaccination schedule and introduction of screening of 
neonates for immunodeﬁ  ciencies could reduce the risk for 
VAPP infection. 
A
fter establishment of the Global Polio Eradication 
Initiative in 1988, the incidence of polio worldwide 
decreased from ≈350,000 cases annually to 1,606 cases 
in 2009 (1). Oral polio vaccine (OPV) has been efﬁ  cient-
ly used for >40 years and is associated with few adverse 
events (2). Its most commonly recognized adverse event, 
vaccine-associated paralytic poliomyelitis (VAPP), is es-
timated by the World Health Organization to cause 1 case 
per million births and by Minor (3) to cause ≈1 case per 6.2 
million doses of OPV distributed.
VAPP is clinically indistinguishable from paralytic 
poliomyelitis caused by wild-type polioviruses (2) and 
occurs among healthy OPV recipients and their contacts, 
with onset temporally linked (within 60 days) to OPV ex-
posure. Persons with primary immunodeﬁ  ciencies are at 
>3,000-fold higher risk for VAPP (2,4). Isolates from im-
munodeﬁ  cient VAPP (iVAPP) patients and some asymp-
tomatic carriers show evidence of prolonged replication 
as indicated by >1% nucleotide sequence divergence from 
the corresponding Sabin OPV strain; such vaccine-derived 
polioviruses (VDPVs) isolated from immunodeﬁ  cient per-
sons after exposure to OPV are called iVDPVs (4,5).
Although most mutations involved in reversion of the 
OPV to a wild-type strain are found in the 5′ untranslated 
region of the virus genome, mutations have also been found 
in viral protein (VP) 1, VP2, and VP3 nt sequences (5). The 
>1% demarcation arises from the average rate of VP1 nt 
divergence of ≈1% per year, suggestive of prolonged rep-
lication (6,7). However, poliovirus evolution rates are vari-
able, especially in the early phases of OPV replication (2). 
Immunodeﬁ  cient OPV vaccine recipients are potential res-
ervoirs for neurovirulent polio virus reintroduction into the 
population (8). To date, >44 cases in patients with immu-
nodeﬁ  ciency have been conﬁ  rmed worldwide that excreted 
iVDPV for long periods (9,10). Timely diagnosis and con-
tainment of VDPVs needs to be addressed in posteradication 
strategies in regions where OPV is still used routinely. We 
present all 6 documented cases of iVAPP caused by iVD-
PVs diagnosed in Iran during 1995–2008 (Tables 1 and 2).
The Study
Patient 1 was a 17-month-old girl. She had exhibited 
antibody deﬁ   ciency and thus received inactivated polio 
vaccine (IPV). She was a household contact of a healthy 
OPV-vaccinated sibling. Limited data indicated that pa-
ralysis became evident in June 1995. All 3 fecal specimens 
collected 3–6 days after onset of paralysis yielded VDPV 
type 2. Recombination with the Sabin 1 strain was detected, 
with a crossover site at nt 5355 (3A). The girl died 8 days 
after onset of paralysis with obscured etiology.
Patient 2 was a boy born in January 2005. He received 
4 doses of OPV, administered at birth and at 2, 4, and 6 
months of age. In August 2005, he was hospitalized with 
irritability, drowsiness, hypotonia, and right paraparesis. 
Two collected fecal specimens tested were positive for 
VDPV type 2. Recombination with the Sabin 1 strain was 
also found at nt 5358. At baseline, he had mild anemia, 
hypogammaglobulinemia, and diminished CD4+ T-cell 
counts. A test result for HIV was negative. The expression 
of human leukocyte antigen DR on his lymphocytes was 
low, indicating major histocompatibility complex class II 
deﬁ  ciency. His condition deteriorated during the next sev-
eral months, with involvement of respiratory muscles and 
3 episodes of aspiration pneumonia. He died of respiratory 
failure at 11 months of age. Follow-up fecal cultures during 
his illness showed persistent VDPV type 2 shedding (11).
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DOI: 10.3201/eid1607.091606Patient 3 was a boy born in January 2006. Beginning 
at 2 months of age, he had chronic diarrhea, malabsorp-
tion, and failure to thrive. Recurrent episodes of pneumo-
nia also developed, beginning when the boy was 4 months 
of age. OPV was administered at birth and at 2, 4, and 6 
months of age. In October 2006, he was referred to hospi-
tal showing symptoms of acute paralysis of the left leg of 
2 weeks’ duration, followed by involvement of his right 
leg and upper arms, accompanied by drowsiness, fever, 
and hypotonia. Laboratory results showed lymphopenia; 
anemia; decreased levels of immunoglobulin (Ig) G, IgA, 
and IgM; and diminished CD3+, CD4+, and CD8+ T-cell 
counts (Table 2). VDPV type 2 was isolated from both of 
his collected fecal specimens. The ﬁ  nal diagnosis was se-
vere combined immunodeﬁ  ciency (SCID) caused by RAG2 
mutation (R229W) (N. Parvaneh, unpub. data). The boy 
died <3 months after onset of paralysis after gram-negative 
sepsis in January 2007.
Patient 4 was a 15-month-old boy who had fever 
and weakness of the lower limbs in December 2006. He 
received 4 doses of OPV, administered at birth and at 2, 
4, and 6 months of age. At admission to the hospital, his 
right leg was completely ﬂ  accid, and the left was paretic. 
VDPV type 3 was isolated from his feces. Recombination 
with the Sabin 1 strain was detected at the 3Dpol region 
of the genome. Immunologic workup showed hypogamma-
globulinemia and diminished CD19+ B lymphocytes. The 
ﬁ  nal diagnosis was X-linked agammaglobulinemia. The 
patient was treated with intravenous Ig and physical thera-
py. Follow-up fecal cultures showed no virus. He died 11 
months after onset of paralysis with chronic respiratory in-
sufﬁ  ciency (12,13).
Patient 5, a girl born in September 2006, was the third 
child of healthy parents. She received OPV at birth and in 
November 2006. In February 2007, she was hospitalized 
with severe pneumonia and paraparesis. Two fecal speci-
mens collected on days 3 and 5 after onset of paralysis were 
positive for VDPV types 1 and 2. B cell–negative T cell–
negative SCID was diagnosed (Table 2); the girl died of 
severe sepsis and multiple organ failure in April 2007, 1 
month after onset of VAPP.
Patient 6, a boy 2 years of age, had weakness in his 
right leg. At 7 months of age, progressive paralysis of the 
extremity developed after a febrile illness. His ﬁ  rst fecal 
specimen was positive for the Sabin 2 strain. He subse-
quently experienced several episodes of pneumonia and 
upper respiratory infections necessitating hospitalization. 
Immunologic workup favored a diagnosis of X-linked 
agammaglobulinemia (Table 2). Electrodiagnostic studies 
of the affected limb indicated femoral nerve mononeu-
ropathy. One of 2 additional fecal specimens collected was 
positive for VDPV type 2. The boy began intravenous Ig 
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Table 1. Age at time of paralysis onset, vaccination history, and characterization of isolated polioviruses, for patients with vaccine-









Viral protein 1 nt 
divergence,† % 
Last OPV and 
 VAPP onset 
Virus shedding 
from VAPP onset 
VAPP onset 
and death 
1 17/F  0‡ 0 1.2 mo  8 d  iVDPV type 2  2.2
2 7/M 4 1.1 mo  3 mo  4 mo  iVDPV type 2  1.1–1.5 
3 10/M 4 3.3 mo  2 wk  1 mo  iVDPV type 2  1.7
4 15/M 4 9 mo  5 mo  11 mo  iVDPV type 3  2
5 5/F  2 3.2 mo  5 d  1 mo  iVDPV type 2, 
iVDPV type 1 
Type 2: 1.7–2; 
type 1: 1.7 
6 20/M 4 1.1 mo  3 d  NA§ iVDPV type 2  1.2
*VAPP, vaccine-associated paralytic poliomyelitis; OPV, oral polio vaccine; iVDPV, immunodeficiency-associated vaccine-derived polioviruses. 
†From the prototype Sabin strain. 
‡Inactivated polio vaccine was administered. Contact case-patient of a healthy OPV-vaccinated sibling. 
§Alive to date, has residual paralysis. 


























NA  NA NA NA NA NA NA NA NA 
2  MHC class II deficiency  6,300  3,642  1,216  608  607  1,460  200  <10  <10 
3 SCID  1,700  731  138  96  32  10  45  <10  <10 
4  XLA  6,500  3,375 2,700 1,404 1,290  35  556  <10  <10 
5  SCID  6,800 2,589  336 184 185 160 <10 <10 <10 
6 XLA  8,500  4,000  2,760  1,920  835  40  20  58  25 
*ALC, absolute lymphocyte count; Ig, immunoglobulin; NA, not available; MHC, major histocompatibility complex; SCID, severe combined 
immunodeficiency; XLA, X-linked agammaglobulinemia. 
†Reference ranges for lymphocyte subpopulations: CD3, 1,900–5,900; CD4, 1,400–4,300; CD8, 500–1,700; CD19, 610–2,600 cells/ȝL. 
‡Reference ranges for immunoglobulins: IgG, 661 ± 219; IgM, 54 ± 23; IgA, 37 ± 18. VAPP in Immunodeﬁ  cient Children, Iran
substitution (600 mg/kg every 4 weeks, continuing to date). 
Follow-up fecal samples became negative for polioviruses. 
His immunodeﬁ  ciency is under control, and he has only 
residual paralysis of the right leg.
Conclusions
Although the Sabin 3 strain is associated with the high-
est rates of VAPP, probably because of low genetic sta-
bility, it is rarely associated with formation of VDPV and 
rarely seen in iVAPP (2). Our ﬁ  ndings were similar, with 
iVDPV type 2 being the most common serotype (detected 
in 5 patients).
In our series, the median interval between administra-
tion of the last OPV dose and iVAPP onset was 3.1 months. 
Khesturiani et al. found a median interval of 2.3 months 
(8). In addition, the median interval between last OPV and 
onset of VAPP in the 23 iVDPV excretors reported dur-
ing 1962–2004 was 0.6 years (2). Immune deﬁ  ciency was 
diagnosed after onset of iVAPP in 5 of our patients. The 
exception is notable because it illustrates one of the few 
iVAPP cases in which immunodeﬁ  ciency was diagnosed 
before paralytic manifestations (14). OPV is routinely ad-
ministered at birth, when most primary immunodeﬁ  cien-
cies are hardly identiﬁ  able (12). Introduction of neonatal 
screening programs for some immunodeﬁ  ciencies such as 
SCID could help prevent inadvertent exposure of such pa-
tients to OPV.
The median interval between last OPV dose and last 
positive sample among the patients in our series was 3.5 
months (range 1.5–14 months). Khesturiani et al. described 
an interval of 8.8 months–7.8 years (8). All the contact 
samples obtained for our cases were negative, implying an 
acceptable coverage of OPV in Iran.
Poliovirus accumulates mutations in VP1 region at 
≈1% per year (6,7). However, our experience shows a more 
rapid evolution (Table 1), assuming that the virus has rep-
licated in the patients’ gastrointestinal systems from birth. 
However, changes in VP1 synonymous third-base codons 
are more constant during virus evolution and are more reli-
able indicators of poliovirus replicative age (4).
Although the risk for further transmission of iVDPV is 
relatively low, potential risk for circulation of iVDPV strains 
always remains. One episode of iVDPV spread (in an Amish 
population with low coverage of OPV) has been document-
ed (15). Because elimination of iVDPV before cessation of 
OPV use seems impossible, changing to an IPV schedule 
seems mandatory for global poliovirus eradication.
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